CONNECTING IMAGING TO CARE

Corporate Presentation

March 2019

2

Disclaimer

This document has been prepared by EOS imaging (the "Company") and is provided for information purposes only. It shall not be construed as or considered as constituting or giving any investment advice. It does not take into account, in any way whatsoever,the investment objectives, financial situation or specific needs of its recipients who/which should not base their investment decision on this document.

This presentation and its contents may not be copied or disseminated, in part or as a whole, without prior written consent of the Company. This presentation includes only summary information and does not purport to be comprehensive.

The information and opinions contained in this document speak only as of the date of this document and may be updated, supplemented, revised, verified or amended, and such information may be subject to significant changes. EOS imaging is not under anyobligation to update the information contained herein and any opinion expressed in this document is subject to change without prior notice. The Company and its affiliates, advisors, representatives or employees shall not have any liability whatsoever (innegligence or otherwise) for any loss whatsoever arising from any use of this document or its contents, or otherwise arising in connection with this document.

The information contained in this document has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to the accuracy, completeness or appropriateness of the information and opinions contained in thisdocument. The Company, its subsidiary, its advisors and representatives accept no responsibility for and shall not be held liable for any loss or damage that may arise from the use of this document or the information or opinions contained herein.

This document contains information on the Company’s markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from the Company’s own estimates.

This presentation may contain forward-looking information and statements pertaining to the Company and its subsidiaries, and its and their results. Forward-looking information is not historical. It reflects objectives that are based on management’s currentexpectations or estimates and is subject to a number of factors and uncertainties, that could cause actual figures to differ materially from those described in the forward-looking statements including those discussed or identified in the documentation publiclyreleased by the Company, including its annual report. EOS imaging draws your attention to the fact that as forward-looking statements cannot under any circumstance be construed as a guarantee of the Company's future performance and that the Company’sactual financial position, results and cash flow, as well as the trends in the sector in which the Company operate may differ materially from those proposed or reflected in the forward-looking statements contained in this document. Furthermore, even if EOSimaging’ financial position, results, cashflows and developments in the sector in which the Company operates were to conform to the forward-looking statements contained in this document, such results or developments cannot be construed as a reliableindication of the Company's future results or developments. The Company does not undertake any obligation to update or to confirm projections or estimates made by analysts or to make public any correction to any prospective information in order to reflectan event or circumstance that may occur after the date of this presentation. A description of those events that may have a material adverse effect on the business, financial position or results of EOS imaging, or on its ability to meet its targets, appears in the"Risk Factors" section of EOS imaging Registration Document registered with the Autorité des Marchés Financiers.

Certain figures and numbers appearing in this document have been rounded. Consequently, the total amounts and percentages appearing in the tables are therefore not necessarily equal to the sum of the individually rounded figures, amounts or percentages.

This presentation is qualified in its entirety by the information contained in the Company ’ financial statements, the notes thereto and the related annual financial report. In case of a conflict, such financial statements, notes and financial reports must prevail.

By accepting this document you agree to be bound by the foregoing limitations.

This document does not constitute or form part of an offer to sell or to purchase securities or the solicitation of an offer to purchase securities in the United States of America or in any other jurisdiction. The securities mentioned in this presentation have notbeen and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or under any other legislation of any jurisdiction in the United States of America and may not be offered or sold in the United States absent registration oran applicable exemption from registration under the Securities Act.

3

EOS imaging: EOSI.PA

Connecting Imaging to Care

~170 employees, including an R&D team of 45 engineers

Clearance to market in 51 countries incl. U.S. (FDA), Japan, China, and the European Union (CE), with >300 units installed worldwide

+25% CAGR over 2012-2018 with 2018 sales revenue of €35.3 million

Unique, innovative, low dose 2D/3D full body imaging and software solutions bridging the gap between imaging and orthopedic surgery

Targeting a ~€2 billion per year addressable market

Direct commercial presence and tactical partnerships with offices in Paris France (HQ), Cambridge Massachusetts, Montreal Quebec, Besançon France, Frankfurt Germany, and Singapore

Created from a technology developed by Dr Georges Charpak, awarded Nobel Prize in Physics, with growing medical endorsements, including >385 publications since 2012

4

Company Milestones

Continued Innovation and Growth

1992

1998

2007

2008

2012

2014

2017

2018

2019

Radiation detection technology used to create EOS imaging was awarded the Nobel Prize in Physics

Initial steps in medical radiology under Marie Meynadier’s leadership

EOS® receives CE mark, initial commercialization team established

FDA clearance received. First EOS systems installed in Europe and North America

EOS imaging listed on Euronext Paris (EOSI)

EOS imaging installs 100th

system globally and authorized to market in 48 countries

Receives FDA clearance on EOSapps surgical planning portfolio and launches EOS 3Dservices

100 EOS systems installed in U.S. and 300 systems globally. EOS Private Practice Program launched in U.S.

Mike Lobinsky transitions into CEO role

5

Management Team

Combined 140+ Years Medical Technology Experience

Mike Lobinsky – Chief Executive Officer

• 20+ years medical device experience including senior management positions at Smith and Nephew, Brainlab, Blue Belt Technologies, Stryker Corp

• Joined EOS imaging in 2017• Appointed CEO January 2019

Valerie Worrall - Chief Financial Officer

• 20+ years finance experience in the healthcare industry including Novartis and previously CFO of Balt

• Joined EOS imaging in 2018

Eric Maulave - Chief Operating Officer

• 25+ years experience including business engineer for the IT and multimedia sectors and international Sales and Marketing Director within the Philips Group

• Joined EOS imaging in 2012

Didier Saint-Felix - Transformation Director

• 30+ years experience in the research and development of innovative medical imaging systems.

• Began his career at the French National Center for Scientific Research (CNRS) and then led R&D at General Electric Healthcare

• Joined EOS imaging in 2006

Kären Solie - Vice President Global Marketing

• 25+ years marketing experience in the medical device industry including senior marketing and market development positions at Stryker, Mako Surgical, superDimension, Covidien (Medtronic), Smith & Nephew and AxoGen

• Joined EOS imaging in 2018

Maurice Delplanque- Vice President of Engineering

• 20+ years experience in R&D and engineering in the healthcare industry

• Contributed to the development of the first digital radiography of neurology and cardiovascular systems at General Electric Healthcare

• Joined EOS imaging in 2007

6

EOS Orthopedic Solution

Low Dose Orthopedic Imaging + 3D Reconstruction + Surgical Planning & Patient Engagement

Imaging 3D Services 3D Surgical Planning & Patient Engagement

EOS systemBiplanar, low dose image capture

Imaging center takes full-body images in a standing or seated position

3D Services3D modeling of musculoskeletal system

Physicians visualize in 3D & obtain a patient-specific dataset of 100+ clinical parameters

automatically

EOSapps 3D surgical planning & patient engagement

Surgeons access surgical simulation and planning from 3D models and data sets

7

The EOS Orthopedic Continuum of Care

Images and Data for Spine, Hip and Knee Conditions and Surgeries

8

Differentiated Orthopedic Imaging Platform

Addressing Weaknesses in Conventional Imaging

1Patients treated for Adolescent Idiopathic Scoliosis had an overall cancer rate 5 times higher than of an age matched populationIncidence of cancer in adolescent idiopathic scoliosis patients treated 25 years previously, Simony A et al. Eur Spine J. 2016

EOS Platform X-ray: CR/DR CT Scanner MRI Ultrasound

Low dose1P P P

3D imaging P P* P*

Full-body(no stitching) P P P

Weight-bearing P P P

Low cost P P

*Only available in non functional positions

EOS Xray

Continuous, full-body imaging

Imprecise, stitched imaging

Bone imaging Soft tissue imaging

Current orthopedic imaging modalities

Exam time cut up to 80% vs

Xray

Dose cut2-10x

vs Xray

9

EOSapps Gaining Traction in Orthopedic Surgery Planning

Web-based, 3D Planning & Simulations of Surgical Outcome

spineEOS› Open architecture (currently) – able to add

vendor specific CAD screws, cages, rods, other

› 3D rod information exportable to rod bender or 3D printer

hipEOS› 3D range of motion simulations of surgical

outcome based on pre-op plan› Better understand patient’s hip & spine

relationship and identify patients at risk of early revision/dislocation

kneeEOS› Real time optimization of knee alignment and surgical

strategy› Automatic proposal of implant size and position according

to EOS images and 2D/3D patient dataset› Open platform, enables compatibility with all primary TKA

implants

Provides for inventory management and optimal instrument set logistics

10

Unique Benefits For All Stakeholders

Patients & Parents

Physicians & Surgeons

Hospitals, Systems& Private Practices

› Bias free clinical parameters, improved planning, correct sizing or choice of implant

› Unique weight-bearing 3D reducing CT imaging needs and providing enhanced understanding of condition

› 2D & 3D data for advanced surgery planning, execution and post-op validation

› Faster exams saving up to 80% time

› Standard of care for ALARA exams

› Key asset to differentiate a hospital’s orthopedic franchise in a competitive environment3

› Reimbursed with existing reimbursement codes

› 3D surgical planning facilitates operational efficiencies

1 1. Diagnostic imaging of spinal deformities: Reducing patients radiation dose with a new slot-scanning x-ray imager. Deschenes S, Charron G, Beaudoin G, Miron M, Labelle H, and Dubois J. et al. Spine. 20102As Low As Reasonably Achievable380% of US hospitals installed in 2017 ran a marketing campaign to inform local community on EOS availability at their facility

› Safer with irradiation 2-10x lower than traditional x-rays1

› Personalized plan for all patient anatomies

› Increased patient engagement from easy to share images

› Increased patient trust from ALARA2

dose commitment

11

~€2b Addressable Market Opportunity

1More than 100 joint orthopedic and/or 30 complex spine surgeries per year, worldwide estimation2Considering: services charged at €200 per surgery with 200 surgeries per EOS platform per year & 1 platform per site

€0,7b €0.5b €0.5b

Equipment +

• €400k ASP• Renewal market for

7 year lifetime• 12,000 sites with

significant orthopedic surgery volumes1

• €45k per unit • Online services and consumables2 (patient specific instruments)

€1.7b

Total

€0.7b

Maintenance Services =

12

Global Sales Channels and Strategic Partnerships

Addressable Market Represents ~12,000 EOS Systems Worldwide

Co-marketing program

Partnership associating EOS equipment to implant volumes in multi-year implant procurement contracts

Direct Sales Distributors & Agents Strategic Partnerships

13

Over 300 Systems Installed Worldwide , of which over 100 in the U.S.

EMEA45.1%NAM

38.6%

Asia-Pac.16.0%

Lat. Am*0.3%

(1)

+18% 2018 Installed Base Growth

+23%2018 Installed Base Growth

+48%2018 Installed Base Growth

+100%2018 Installed Base Growth

*1st system installed in 2017 + one additional one installed in 2018

+ 25% installed base growth in 2018

14

› Privately owned orthopedic practices operate their own imaging equipment

› 10 private practices purchased EOS

Expansion Beyond Hospital Market

Growing Adoption in Imaging Centers & Orthopedic Private Practices France: 72 EOS Installed 60% In Private Imaging Centers

› 2/3 of radiologists are in private sector

› Serving orthopedic surgery private clinics

Australia: 20 EOS Installed70% In Private Imaging Centers

Germany: 13 EOS Installed 40% In Private Settings

› Serving orthopedic private clinics

U.S.: 110 EOS InstalledLaunched Orthopedic Private Practice Program

› Serving orthopedic surgery hospitals and private clinics

15

U.S. Market Opportunity

~2% Penetration Rate

~ 1,000 tier one hospitals

~ 5,000 hospitals

(w/ inpatient treatment)

~100+ installed

Private Ortho Groups Practice

~ 750 tier one Practices

~ 1,600 private practices

(w/o inpatient treatment)

10+ installed

16

Increasing Adoption by Top Ranked Hospitals in U.S.

Proven Solution Drives Repeat System Purchases

EOS in the 25 Best Orthopedic Hospitals:84% of the Pediatric Hospitals64% of the General Hospitals

EOS in the top 10 Best Hospitals Honor Roll:90% of the Pediatric Hospitals80% of the General Hospitals

Constant growth of sites with more than 1 EOS system

4th HSS system to be installed in 2019

17

U.S. Private Orthopedic Practice Adoption

• «EOSone» program launched in 2018 (EOS program customized for Private Ortho Practice setting)• Benefits for clinics:

• Leverage EOS technology to differentiate practice and ASC• Offer end to end imaging to planning to surgery solution• Fair financial Return On Investment • Increased referrals

EOSone Program Components

EOS Private Practice Locations

18

• EOS Maintenance Agreements • Increasing subscription rate driving accelerated growth in

maintenance contracts

• Advanced Orthopedic Services (3DServices and EOSapps Surgical Planning)*• 30+% of current U.S. customer base under contract • Initial “try and buy” programs converting to future revenues • Including AOS “starter offering” in all EOS system sales• Implant company library growing

Recurring Revenue Acceleration

EOS Maintenance and Software Services Traction

*EOS also has a legacy PSI business (ca. €0.9m) which is stable and not a development focus

19

Sales of €35.3m in 2018

Recurring revenues represented 25% of total sales in 2018, compared to 10% of total sales in 2012

25% CAGR

Revenue growth

20

Revenues by Product and Region

Revenues Noted in €

21

Pillars of Growth

SalesTeam tenure and opportunity

pipeline in place to deliver growth

Business Development2019 is expansion year

for 3DServices & EOSapps

Product DevelopmentContinuing to expand end to end

portfolio

› Development of sales pipeline by new team in 2018 to deliver growth plans in 2019 and beyond

› Chinese distributor change to enhance EOS focus and coverageacross China

› Advanced Orthopedic Solutions (AOS) organization in place to drive accelerated market adoption in 2019

› Expecting 2018 AOS trial agreements to convert to purchase

› Ongoing discussions with implant companies

Continued development on differentiated EOS orthopedic solution

› AI / Machine Learning

› Predictive analytics

› Pre op surgical simulation

› EOS Apps portfolio enhancements

CONNECTING IMAGING TO CARE

Contact:

Phone: +33 (0)1 55 25 60 60

Email: investors@eos-imaging.com

www.eos-imaging.com

March 2019